Local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients: Results of a randomized controlled trial
Objectives: Consequences of COVID-19 on olfactory functions remained unclear during the pandemic. We assessed the efficacy of local budesonide in addition to olfactory rehabilitation when managing non-severe COVID-19 patients with persistent hyposmia. Methods: A multicentric, randomized, superiority trial was conducted (ClinicalTrials.gov NCT04361474). The experimental group (EG) received budesonide and physiological saline nasal irrigations administered via three syringes of 20 ml in each nasal cavity in the morning and evening for 30 days. The control group (CG) received a similar protocol without budesonide. Patients were included if they were <18 years old, with a SARS-CoV-2 infection and presenting an isolated hyposmia persisting 30 days after symptom onset. The primary endpoint was the percentage of patients with improvement of more than two points on the ODORATEST score after 30 days of treatment. Results: In total, 123 patients were included and randomized (EG: 62 vs CG: 61). Two patients from the EG met the primary endpoint with no statistical difference between the two groups (P = 0.5). Conclusion: To our knowledge, this is the first study evaluating local budesonide for COVID-19 related hyposmia treatment even though previous trials were performed with other local corticosteroids. Local budesonide efficacy was not demonstrated for persistent hyposmia related to COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:136 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 136(2023), Seite 70-76 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Charlotte Hautefort [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Budesonide |
|---|
| doi: |
10.1016/j.ijid.2023.08.022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ096687967 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ096687967 | ||
| 003 | DE-627 | ||
| 005 | 20240413155144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2023.08.022 |2 doi | |
| 035 | |a (DE-627)DOAJ096687967 | ||
| 035 | |a (DE-599)DOAJ2ad2b32541e447b2b95336cdda095216 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Charlotte Hautefort |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients: Results of a randomized controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objectives: Consequences of COVID-19 on olfactory functions remained unclear during the pandemic. We assessed the efficacy of local budesonide in addition to olfactory rehabilitation when managing non-severe COVID-19 patients with persistent hyposmia. Methods: A multicentric, randomized, superiority trial was conducted (ClinicalTrials.gov NCT04361474). The experimental group (EG) received budesonide and physiological saline nasal irrigations administered via three syringes of 20 ml in each nasal cavity in the morning and evening for 30 days. The control group (CG) received a similar protocol without budesonide. Patients were included if they were <18 years old, with a SARS-CoV-2 infection and presenting an isolated hyposmia persisting 30 days after symptom onset. The primary endpoint was the percentage of patients with improvement of more than two points on the ODORATEST score after 30 days of treatment. Results: In total, 123 patients were included and randomized (EG: 62 vs CG: 61). Two patients from the EG met the primary endpoint with no statistical difference between the two groups (P = 0.5). Conclusion: To our knowledge, this is the first study evaluating local budesonide for COVID-19 related hyposmia treatment even though previous trials were performed with other local corticosteroids. Local budesonide efficacy was not demonstrated for persistent hyposmia related to COVID-19. | ||
| 650 | 4 | |a Budesonide | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Persistent hyposmia | |
| 650 | 4 | |a Olfactory rehabilitation | |
| 650 | 4 | |a ODORATEST | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Alain Corré |e verfasserin |4 aut | |
| 700 | 0 | |a Guillaume Poillon |e verfasserin |4 aut | |
| 700 | 0 | |a Clément Jourdaine |e verfasserin |4 aut | |
| 700 | 0 | |a Juliette Housset |e verfasserin |4 aut | |
| 700 | 0 | |a Michael Eliezer |e verfasserin |4 aut | |
| 700 | 0 | |a Benjamin Verillaud |e verfasserin |4 aut | |
| 700 | 0 | |a Dorsaf Slama |e verfasserin |4 aut | |
| 700 | 0 | |a Denis Ayache |e verfasserin |4 aut | |
| 700 | 0 | |a Philippe Herman |e verfasserin |4 aut | |
| 700 | 0 | |a Amélie Yavchitz |e verfasserin |4 aut | |
| 700 | 0 | |a Jessica Guillaume |e verfasserin |4 aut | |
| 700 | 0 | |a Camille Hervé |e verfasserin |4 aut | |
| 700 | 0 | |a Wissame El Bakkouri |e verfasserin |4 aut | |
| 700 | 0 | |a Dominique Salmon |e verfasserin |4 aut | |
| 700 | 0 | |a Mary Daval |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 136(2023), Seite 70-76 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:136 |g year:2023 |g pages:70-76 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2023.08.022 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/2ad2b32541e447b2b95336cdda095216 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971223007075 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 136 |j 2023 |h 70-76 | ||